RECRUITING

Novel Strategies for Reducing Burn Scar Itch

Talk to us

Conditions

Burn ScarItch ScarringWoundItchBurnDiphenhydramineFamotidine

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of the study is to see whether using diphenhydramine (Benadryl), famotidine (Pepcid), and cromolyn sodium will decrease burn scar itch.

Official Title

Novel Strategies for Reducing Burn Scar Itch

Quick Facts

Study Start:2025-03-01
Study Completion:2027-11-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06801626

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 80 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Participant has provided informed consent in a manner approved by the IRB and is willing and able to comply with the trial procedures.
  2. * Adults: ≥18 to \<80 years of age.
  3. * Has an itchy burn scar.
  1. * Failure to obtain consent or unable to return for follow up assessments.
  2. * Patient is unable to follow the protocol required assessments.
  3. * Member of a vulnerable class (e.g., prisoners, pregnant participant, etc.).
  4. * Any medical condition that, in the opinion of the investigator or physician, would place the participant at increased risk for participation.
  5. * Concurrent participation in another interventional clinical trial (to avoid confounding factors that may influence outcomes).
  6. * History of prior non-compliance or the presence or history of psychiatric condition (including drug or alcohol addiction) that would, in the opinion of the investigator, make it difficult for the participant to comply with the study procedures or follow the investigators instructions.
  7. * Age \< 18 or ≥ 80 years.
  8. * Taking one of the following medications: cefuroxime, dasatinib, delavirdine, neratinib, pazopanib, risedronate, or tizanidine.
  9. * Has a pre-existing inflammatory or itchy skin disease.
  10. * Is taking an H2 antihistamine for another indication.

Contacts and Locations

Study Contact

Lindsey Allen, RN
CONTACT
409-266-2678
listurm@utmb.edu

Principal Investigator

Celeste Finnerty, PhD
PRINCIPAL_INVESTIGATOR
University of Texas Medical Branch, Galveston

Study Locations (Sites)

University of Texas Medical Branch, Galveston
Galveston, Texas, 77555
United States

Collaborators and Investigators

Sponsor: The University of Texas Medical Branch, Galveston

  • Celeste Finnerty, PhD, PRINCIPAL_INVESTIGATOR, University of Texas Medical Branch, Galveston

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-03-01
Study Completion Date2027-11-01

Study Record Updates

Study Start Date2025-03-01
Study Completion Date2027-11-01

Terms related to this study

Keywords Provided by Researchers

  • Itch
  • Burn
  • Diphenhydramine
  • Famotidine

Additional Relevant MeSH Terms

  • Burn Scar
  • Itch Scarring
  • Wound